womens health

Estrigenix Therapeutics, Inc. presents at 2nd ACE Drug Discovery Summit 2024 in London

MILWAUKEE (March 21, 2024) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is proud to have been a presenter at the ACE Drug Discovery Summit 2024 in London. William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix presented an abstract entitled, “Discovery of Selective Estrogen Receptor Beta … Estrigenix Therapeutics, Inc. presents at 2nd ACE Drug Discovery Summit 2024 in London

Estrigenix invited to present at the Science2Startup Symposium in Boston, April 10th

MILWAUKEE (March 8, 2024) – Estrigenix Therapeutics, Inc., was selected to speak at Science2Startup symposium in Boston on April 10th. The Symposium is an invitation-only event focused on bringing academic innovations to the attention of the Boston-based venture capital ecosystem. Estrigenix was selected as one of eight teams to present, out of over 132 submissions. … Estrigenix invited to present at the Science2Startup Symposium in Boston, April 10th

CSO Karyn Frick discusses “Why women are more likely to develop Alzheimer’s Disease” on Chicago radio WLS 890AM (the Big 89)

MILWAUKEE (October 25, 2023) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company is leading the way in estrogen biology. Karyn Frick, Ph.D, chief scientific officer of Estrigenix spoke with Rob Johnson and Jane Clauss of Chicago radio “The Big 89” regarding Alzheimer’s Disease and the increased risk for women developing AD. It has … CSO Karyn Frick discusses “Why women are more likely to develop Alzheimer’s Disease” on Chicago radio WLS 890AM (the Big 89)

Estrigenix Therapeutics to Attend The Menopause Society Meeting

MILWAUKEE (Sept. 22, 2023) – Estrigenix Therapeutics, Inc., is announcing Patricia Scheller, Executive Chairwoman, and Daniel Sem, VP for Business Development will attend the The Menopause Society, (formerly known at the North American Menopause Society) Annual Meeting in Philadelphia September 27 – 30, 2023. The Menopause Society is the premier organization for health professionals with … Estrigenix Therapeutics to Attend The Menopause Society Meeting

Estrigenix Therapeutics one of five Wisconsin companies awarded SBIR Advance Phase 1 funding from WEDC

Estrigenix Therapeutics was one of five Wisconsin-based companies awarded matching funding from the SBIR Advance Phase 1 program funded by the Wisconsin Economic Development Corporation. The SBIR Advance program provides assistance to companies in the process of completing a project in the federal Small Business Innovation Research (SBIR) program. feedback and reviewed multiple proposals from … Estrigenix Therapeutics one of five Wisconsin companies awarded SBIR Advance Phase 1 funding from WEDC

Estrigenix Therapeutics, Inc. presents at Precision Drug Discovery & Preclinical Summit 2023 in Boston

MILWAUKEE (June 15, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is proud to have been a presenter at the Precision Drug Discovery & Preclinical (PDDP) Summit 2023 in Boston. William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix presented an abstract entitled, “Discovery of Selective … Estrigenix Therapeutics, Inc. presents at Precision Drug Discovery & Preclinical Summit 2023 in Boston

Estrigenix CSO Karyn Frick Featured on “FemTech Focus” Podcast

MILWAUKEE (May 16, 2023) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, was recently featured on the podcast FemTech Focus hosted by Brittany Baretto, PhD. Karyn Frick, Ph.D, chief scientific officer of Estrigenix spoke with Dr. Baretto regarding Estrigenix’s first-in-class therapeutics to treat and prevent hot flashes … Estrigenix CSO Karyn Frick Featured on “FemTech Focus” Podcast

Estrigenix Therapeutics, Inc.’s Chief Scientific Officer Karyn Frick PhD featured in Center for Technology Commercialization

Estrigenix Therapeutics,  Inc.’s chief scientific officer, Karyn Frick PhD was recently featured in Center for Technology Commercialization talking about the process Estrigenix went through to receive Small Business Innovation Research (SBIR) Ready funding. The SBIR Ready program provided feedback and reviewed multiple proposals from Estrigenix before giving Estrigenix the green light for the SBIR Ready … Estrigenix Therapeutics, Inc.’s Chief Scientific Officer Karyn Frick PhD featured in Center for Technology Commercialization

Karyn Frick, Ph.D Featured on “Beyond the Paper Gown” Podcast

MILWAUKEE (Dec. 8, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, was recently featured on the podcast Beyond the Paper Gown™ hosted by Mitzi Krockover, MD. Karyn Frick, Ph.D, chief scientific officer of Estrigenix spoke with Dr. Krockover regarding Estrigenix’s first-in-class therapeutics to treat and prevent … Karyn Frick, Ph.D Featured on “Beyond the Paper Gown” Podcast

Estrigenix Appoints Patricia Scheller as Executive Chairwoman

MILWAUKEE (Dec. 5, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is excited to announce Patricia Scheller as its executive chairwoman.    In this role, Scheller will be actively involved in Estrigenix’s business. She will chair the board of directors, act as an advisor to William Donaldson, … <strong>Estrigenix Appoints Patricia Scheller as Executive Chairwoman</strong>